DBGen Ocular Genomics, 08028 Barcelona, Spain.
Departament de Genètica, Microbiologia i Estadística, Facultat de Biologia, Universitat de Barcelona, Avda.Diagonal 643, 08028 Barcelona, Spain.
Genes (Basel). 2019 Sep 21;10(10):732. doi: 10.3390/genes10100732.
The aim of this study was the genetic diagnosis by next generation sequencing (NGS) of a patient diagnosed with Usher syndrome type 2 and the functional evaluation of the identified genetic variants to establish a phenotype-genotype correlation.
Whole exome sequencing (WES) analysis identified two heterozygous intronic variants in , a gene responsible of Usher syndrome type 1. Evaluation of the putative splicing effects was performed in vivo, in whole blood samples, and in vitro, by transfection of midigene constructs in HEK293T cells.
Two intronic variants were identified in intron 45 of -one novel, c.6050-15G>A, and the other, c.6050-9G>A, already reported as a noncanonical splice site (NCSS) mutation-with partial functional characterization. In vivo and in vitro analyses showed aberrant transcripts by the addition of 13 and 7 nucleotides to exon 46, respectively. Transcript degradation by nonsense mediated decay (NMD) in blood cells could only be prevented by cycloheximide treatment. Midigene constructs showed that the two variants contributed to exon skipping and generated aberrantly spliced transcripts.
A combination of in vivo and in vitro assays provided a comprehensive view of the physiological effects of NCSS variants, which in this case led to a clinical reassignment of the proband as affected with atypical USH1 syndrome.
本研究的目的是通过下一代测序(NGS)对诊断为 2 型乌谢尔综合征的患者进行基因诊断,并对鉴定的遗传变异进行功能评估,以建立表型-基因型相关性。
全外显子组测序(WES)分析在 基因中鉴定出两个杂合内含子变异体,该基因负责 1 型乌谢尔综合征。在全血样本中进行体内评估,并在体外通过转染 midigene 构建体在 HEK293T 细胞中评估潜在的剪接效应。
在 基因的内含子 45 中鉴定出两个内含子变异体-一个新的 c.6050-15G>A,另一个是 c.6050-9G>A,已报道为非典型剪接位点(NCSS)突变-具有部分功能特征。体内和体外分析显示,分别在第 46 外显子中添加了 13 和 7 个核苷酸的异常转录本。通过环己酰亚胺处理只能防止血液细胞中无义介导的衰变(NMD)引起的转录本降解。midigene 构建体表明,这两个变异体导致外显子跳跃,并产生异常剪接的转录本。
体内和体外试验的组合提供了 NCSS 变异体的生理效应的全面视图,在这种情况下,导致先证者被重新归类为非典型 USH1 综合征。